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The work was aimed at developing novel enteric coated HPMC capsules (ECHC) plugged with 5 
Florouracil (5-FU) loaded Microsponges in combination with calcium pectinate beads. Modified quasi-
emulsion solvent diffusion method was used to formulate microsponges based on 32 factorial design 
and the effects of independent variables (volume of organic solvent and Eudragit RS100 content) on the 
dependent variables (Particle size, %EE & % CDR) were determined. The optimized microsponges (F4) 
were characterized by SEM, PXRD, TGA and were plugged along with calcium pectinate beads in HPMC 
capsules and the HPMC capsules were further coated with enteric polymer Eudragit L 100 (Ed-L100) 
and/ or Eudrgit S 100 (Ed-S 100) in different proportions. In vitro release study of ECHC was performed 
in various release media sequentially SGF for 2 h, followed by SIF for the next 6 h and then in SCF (in 
the presence and absence of pectinase enzyme for further 16 h). Drug release was retarded on coating 
with EdS-100 in comparison to blend of EdS-100: EdL-100 coating. The percentage of 5-FU released 
at the end of 24 h from ECHC 3 was 97.83 ± 0.12% in the presence of pectinase whereas in control 
study it was 40.08 ± 0.02% drug. The optimized formulation was subjected to in vivo Roentgenographic 
studies in New Zealand white rabbits to analyze the in vivo behavior of the developed colon targeted 
capsules. Pharmacokinetic studies in New Zealand white rabbits were conducted to determine the extent 
of systemic exposure provided by the developed formulation in comparison to 5-FU aqueous solutions. 
Thus, enteric coated HPMC capsules plugged with 5-FU loaded microsponges and calcium pectinate 
beads proved to be promising dosage form for colon targeted drug delivery to treat colorectal cancer.
Uniterms: 5-Fluorouracil. HPMC capsules/enteric coating. Microsponges/formulation. Drugs/delivery/
colon targeting. Colorectal cancer/treatment.
O trabalho teve como objetivo o desenvolvimento de novas cápsulas com revestimento entérico HPMC 
(ECHC) conectadas com microesponjas carregadas com fluoruracila (5-FU) em combinação com grânuos 
de pectinato de cálcio. O método de difusão de solvente modificado quasi-emulsão foi usado para formular 
microesponjas com base no planejamento fatorial 32 e determinaram-se os efeitos das variáveis independentes 
(volume de solvente orgânico e conteúdo Eudragit RS100) sobre as variáveis dependentes (tamanho de 
partícula, EE% e % CDR). As microesponjas otimizadas (F4) foram caracterizadas por SEM, PXRD, TGA 
e ligadas aos grânulos de pectinato de cálcio em cápsulas de HPMC e estas foram, ainda, revestidas com 
polímero entérico Eudragit L 100 (Ed-L100) e/ou Eudrgit S 100 (Ed S 100) em diferentes proporções. 
No estudo de liberação in vitro de ECHC foi realizada em vários meios de liberação sequencial SGF 
durante 2 h, seguido de SIF para as próximas 6 h, e, em seguida, em SCF (na presença e na ausência de 
enzima pectinase por mais 16 h). A liberação do fármaco foi retardada em revestimento com a EDS-100, 
em comparação com mistura de EDS-100: EDL-100, de revestimento. O percentual de 5-FU liberado de 
ECHC 3 ao final de 24 h foi 97,83 ± 0,12% em presença de pectinase, enquanto que para o controle foi de 
40,08 ± 0,02% do fármaco. A formulação otimizada foi submetida a estudos Roentgenográficos in vivo, em 
coelhos brancos Nova Zelândia, para analisar o comportamento das cápsulas desenvolvidas direcionadas 
ao cólon. Os estudos de farmacocinética em coelhos brancos da Nova Zelândia foram conduzidos para 
determinar a extensão da exposição sistêmica propiciada pela formulação desenvolvida, em comparação com 
solução aquosa de 5-FU. Assim, cápsulas entéricas de HPMC revestidas e conectadas com microesponjas 
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carregadas com 5-FU e grânulos de pectinato de cálcio se mostraram promissoras como formulação para 
liberação do fármaco no cólon no tratamento do câncer colorretal.
Unitermos: Fluoruracila. Cápsula de HPMC/revestimento entérico. Microesponjas/formulação. Fármaco/
liberação/direcionamento para o cólon. Câncer colorretal/tratamento.
INTRODUCTION
Cancer is one of the most challenging diseases to 
cure and the second leading cause of death in developing 
countries. Over the past few decades, it continues to be a 
worldwide health problem in spite of several advanced 
technologies (Wolpin, Mayer, 2008). Cancers of the colon 
and rectum, often collectively referred to as colorectal 
cancer, are life-threatening tumors that develop in the large 
intestine. More than 80% of colorectal tumors develop 
from adenomatous polyps. Their numbers increase with 
age. Polyps are found in about 25% of people by age 50, 
and 50% of people by age 75. Fewer than 1% of polyps 
less than 1 centimeter (slightly less than half an inch) 
becomes cancerous. About 10% of larger polyps become 
cancerous within 10 years, and about 25% of these larger 
polyps become cancerous after 20 years.
Drug delivery systems based on calcium pectinate 
beads have been recently investigated for specific-
targeting drugs to the colon (Badve et al., 2007). 
Such systems, obtained by pectin gelatinization in the 
presence of calcium salts, are less water-soluble than 
natural pectins, since calcium ions induce non-covalent 
associations of carbohydrate chains through the formation 
of the so-called ‘‘egg box complexes’’ but they maintain 
the selective biodegradation by pectinolytic enzymes of 
colonic bacteria microflora (Jain, Gupta, Jain, 2007).
Microsponges are polymeric delivery systems 
composed of porous microspheres. They are tiny sponge like 
spherical particles that consist of a myriad of interconnecting 
voids within a non-collapsible structure with large porous 
surface (Srivastava, Kumar, Pathak, 2010). The reasons 
for fabricating microsponge was due to the fact that, drug 
carrier systems less than 200 μm can efficiently be taken 
up by the macrophages present in colon tissue, thus exhibit 
effective localized drug action at the desired site. Apart from 
being site specific, retention of drug or its carrier system on 
the colonic surface is yet another important consideration 
that guided the selection of microsponges as the drug carrier 
system in the research work (Orlu, Cevher, Araman, 2006). 
They can also increase the lag time for absorption of drug 
as these get entrapped on the surface of the colon and thus 
have the potential for being developed as a colon-targeted 
drug delivery system.
The objective of our research work was to design 
novel enteric coated HPMC capsules (ECHC) plugged 
with 5-FU loaded microsponges in combination with 
calcium pectinate beads. 32 full factorial design was 
used to optimize microsponges prepared by modified 
quasi-emulsion solvent diffusion method using a sodium 
chloride as porogen.
5-FU was chosen as a model drug for our research 
work because targeted delivery of 5-FU not only reduces 
systemic side-effects, but also provide an effective and safe 
therapy for colon cancer with reduced dose and reduced 
duration of therapy (Chickpetty, Raga, 2013). Longer 
exposure to lower concentration of 5-FU has been reported 
by researchers to favor DNA-directed effects which is 
thought to contribute to its anti-tumor effect .
In our research work HPMC capsule was preferred 
over gelatine capsules because HPMC capsule had slower 
drug release profile in acidic media and the fast release 
profile at a pH of 5 and above (Huyghebaert, Vermeire, 
Remon, 2004). This can result in lower quantities of 
polymer coat compared with that required for tablets 
to achieve the desired release in the small intestine or 
colon. Surprisingly, it was also found that enteric coated 
HPMC capsules offer much higher resistance against acid 




5-FU (Shalaks Pharmaceutical Pvt. Ltd, New Delhi); 
HPMC Capsules (ACG Associated Capsules Pvt. Ltd, 
SciTech Centre, Mumbai); Eudragit RS100, Eudragit 
S100 (EdS100) and Eudragit L100 (EdL100) (Evonik 
Labs, Mumbai) were obtained as gifts from the suppliers. 
All other chemicals used were of analytical grade and 
purchased from authentic suppliers.
Method development for the fabrication of 
microsponges
Previously described methods of microsponge 
preparation by quasi emulsion solvent diffusion technique 
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using porogen (Bae et al., 2009; Graves et al., 2005) were 
modified to employ an aqueous solution of sodium chloride 
as porogen. 1% (w/v) aqueous solution of the porogen 
(NaCl) was prepared and sufficient amount of Span 80 was 
added to it with agitation to obtain1% (v/v) dispersion. A 
solution of the Eudragit RS 100 and 5-FU was prepared 
in a mixture of Ethanol: DCM and the porogen solution 
(0.1 mL) was uniformly emulsified in it, to form a w/o 
emulsion. 5% (w/v) aqueous PVA solution (external phase) 
was prepared separately and the previously prepared w/o 
emulsion was emulsified in it. This w/o/w emulsion was 
stirred for 24 h to get microsponges that were filtered, dried 
at 60 oC and stored in a desiccator (Srivastava, Kumar, 
Pathak, 2010).
Optimization of microsponges via 32 factorial 
design
A 32 randomized full factorial design was run 
to optimize the variables. In this design two factors 
were evaluated, each at 3 levels, and experimental 
trials were performed at all nine possible combinations 
using Design Expert Software 8.0.7.1 (Stat-Ease, Inc., 
Minneapolis, USA). In the present investigation, volume 
of organic media (X1) and amount of polymer content 
(X2) were selected as independent variables and total 
nine microsponge formulations (F1–F9) were fabricated 
by varying these variables as given in Table I. The 
particle size, % EE and % CDR selected as dependent 
variables and Polynomial equations were generated for 
the dependent variables that were reduced by removing 
non-significant coefficients by applying one way ANOVA. 
To demonstrate graphically the influence of each factor on 
the responses, the response surface plots and 3D bar graph 
were generated. The value of P<0.05 was considered to 
be significant.
·	 Validation of experimental design
The formulation developed was evaluated for the 
responses and the experimental values obtained were 
compared with those predicted by the mathematical 
models generated (F 10).
·	 Selection of optimized formulation
A numerical optimization technique using the 
desirability approach was employed to select the 
optimized formulation with desired responses. Constraints 
like maximizing entrapment efficiency & % drug release at 
the end of 8 h as well as minimizing particle size were set 
as goals to select the optimized formulation using Design 
Expert Software 8.0.7.1 (Stat-Ease, Inc., Minneapolis, 
USA). Optimized formulation was plugged in enteric 
coated colon target capsules.
Characterization of microsponges
·	 Morphological studies and rheological characteriza-
tion
Morphological characteristics of microsponges 
were studied by scanning electron microscopy (Hitachi, 
S 3000H Japan). The microsponges were dotted on an 
adhesive tape attached to an aluminium stub and excess 
microsponges were detached. To render the particles 
electrically conductive, the stub spotter was coated with 
gold using a vacuum evaporator. The coated Microsponges 
were viewed at 10 kV.
TABLE I - 32 Factorial design model for the fabrication of 5-FU loaded microsponges
S. No. Formulation Code
Independent Variables




1 F1 (+1) 8 (+1) 1200 Particle Size (Y1)
2 F2 (-1) 6 (-1) 400 % EE (Y2)
3 F3 (0) 7 (0) 800 % CDR (Y3)
4 F4 (+1) 8 (-1) 400
5 F5 (-1) 6 (+1) 1200
6 F6 (0)7 (-1) 400
7 F7 (-1) 6 (0) 800
8 F8 (0)7 (+1) 1200
9 F9 (+1) 8 (0)800
10 F10 (extra design check point) (+0.5)7.5 (-0.5) 600
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·	 Powder X- ray diffraction studies (PXRD)
The crystalline behavior of the drug before and 
after encapsulation, was evaluated by X-ray powder 
diffractometer (Bruker D8 Discover, Germany) using a 
CuK alpha radiation source with the Ni-filter. A scanning 
rate of 5o min-1, tube voltage of 35 KV and current of 35 
mA over a range of 16-60o were used in measurement.
·	 Thermal analysis
Differential scanning calorimetry and Thermo 
gravimetric analysis of the pure drug and drug-loaded 
microsponges were carried out with simultaneous TGA 
/ DSC analyzer (Mettler Toledo TGA/ DSC, USA). An 
amount 13.714 mg of drug and 9.35 mg of drug loaded 
microsponges was placed in aluminium pans and sealed 
prior to the test. All samples were run at a heating rate 
of 10 ºC/min over a temperature range 30–600 °C in an 
atmosphere of nitrogen.
·	 Particle size
All Formulations of the microsponges were 
analyzed for particle size by an optical microscope. The 
instrument was calibrated and found that 1unit of eyepiece 
micrometer was equal to 7 μm. Sizes of 100 microsponges 
were calculated in 10 X magnification.
·	 Determination of drug content, drug loading and 
entrapment efficiency (EE)
A sample of drug loaded microsponges (50 mg) 
was dissolved in 50 mL of phosphate buffer (pH 7.4) 
by using ultrasonicator and kept for overnight. Filtered 
Samples were appropriately diluted and analyzed 
spectrophotometrically at 266 nm. Percent drug content, 
% entrapment efficiency and % drug loading were 
calculated.
·	 In vitro drug release studies of microsponges
Microsponges equivalent to 50 mg of drug were 
filled in HPMC capsules and placed in the basket (mesh 
#230 = 63 µm) of USP apparatus 1 and the study was 
performed in the 900 mL of simulated colonic fluid 
(SCF) without pectinase for 8 h at 50 rpm, maintained 
at 37 ± 0.5 ºC. Aliquots were withdrawn periodically 
and sink conditions were maintained by adding equal 
amounts of release medium. The samples were analyzed 
spectrophotometrically and % cumulative drug release 
(CDR) versus time plots was constructed. Data obtained 
from in-vitro release studied was evaluated to check the 
goodness of fit to various release kinetics equations for 
quantifying the phenomena controlling the release of drug 
from microsponges (Costa, Lobo, 2001).
Modification of pectin and its characterization
Pectin was crosslinked by the ionotropic gelation 
method. A 10% (w/v) aqueous Pectin dispersion was 
added drop wise into gently stirred 100 mL of 10% (w/v) 
aqueous solution of calcium chloride pre-adjusted to pH 
5.5. The gelled particles were left in the medium for 10 
min, washed with deionized water and dried at 60 oC. The 
particles were screened through sieve no 44 and kept in 
a desiccator to remove the traces of moisture and then 
evaluated for morphological, rheological and swelling 
characteristics (Sharma, Philip, Pathak, 2008).
Preparation and evaluation of enteric coated 
HPMC capsules
Each batch of HPMC capsules was coated with 
enteric polymer EdS100 / EdL100 or bend of EdS100 and 
EdL100 in different ratios, by dip coating method in the 
polymeric solution of EdS100 and EdL100 to ensure the 
formation of a uniform and thin covering over the capsule. 
In order to enhance the elasticity of EUDRAGIT films, 
1.25% of dibutyl phthalate as plasticizer was added to 
the coating solution. HPMC bodies and caps were coated 
separately to ensure coverage of the body with polymer, 
especially where the cap overlaps (Huyghebaert, Vermeire, 
Remon, 2004). Coated bodies were filled by formulation 
matrix consisting of 50 mg drug loaded microsponges 
plugged along with 5, 10, 15% w/ w of calcium pectinate 
beads and the rest of the volume was adjusted by inert 
lactose and finally closed with the coated caps. The joint 
of the capsule was sealed with a small amount of 5% EdS 
100 solution. For each polymeric solution coating of the 
capsules was made with different thickness ratios. The 
capsules were allowed to dry with the help of dryer with 
an inlet temperature of 35-40 ºC and observed for coat 
uniformity, pores and cracks under microscope.
·	 Integrity test of enteric coated HPMC capsules
Prior to the dissolution test enteric-coated HPMC 
capsules were subjected to a disintegration test in 0.1 M 
HCl for 2 h to determine the ability of the coat to withstand 
acid environment. Afterwards, the capsules were dried at 
25 oC for 45 min, thereafter; the capsules were subjected 
to microscopic examination to check for the integrity of 
the coat. The enteric coated capsules, which passed the 
disintegration test were further evaluated for integrity of 
the coating in pH 5.5 since the dissolution of the coating in 
pH lower than 6.8 may alter the required lag time. On the 
basis of solubility in pH 5.5 buffer, coating compositions 
and levels that fell short were rejected to avoid alteration 
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of lag time. Only coating levels and compositions which 
were not dissolved at all or dissolved very slowly in pH 
5.5 buffer were selected for further in vitro drug release 
studies (Cole et al., 2002).
·	 In vitro drug release study of ECHC
The study was performed in USP drug release 
apparatus in various release media sequentially SGF (pH 
1.2) for 2 h, followed by SIF (pH 7.4) for the next 6 h and 
then in SCF (presence and absence of pectinase, for further 
16 h). The test conditions were 900 ml of medium stirred 
at 50 rpm and maintained at 37 ± 0.5 oC. Aliquots were 
withdrawn at regular intervals and replaced with an equal 
amount of the fresh medium to maintain sink condition. 
The samples were analyzed for 5-FU content released at 
265.4 nm. Concomitantly the swelling characteristics and 
physical behavior of capsules were observed at 0, 2, 5, 8, 
10, 14, 18 and 24 h and recorded visually. The systematic 
evaluation of ECHC-3, ECHC-14, and ECHC-15 led to 
identification of optimized formulation.
Animal studies
All the animal experiments have been conducted 
in full compliance with the institutional ethical and 
regulatory principles and as per the spirit of the Association 
for Assessment and Accreditation of Laboratory Animal 
Care & International’s expectations for animal care and 
use/ethics committees. The investigations were performed 
after obtaining approval by the Institutional Animal 
Ethical Committee of PSIT, Kanpur, India (IAEC no: 
IAEC/PSIT/1273/ac/13).
·	 In vivo roentgenographic study
The 5-FU loaded microsponges in colon targeted 
capsules were partially replaced with barium sulfate 
microsponges (Chickpetty, Raga, 2013). The reformulated 
enteric polymer coated capsules were administered orally 
with 15 ml of water, to New Zealand white rabbits (n = 3; 
3–3.5 kg) that were fasted overnight with free access to 
water. Fluoroscopic images of the abdomen of the rabbits 
were taken before administration (0 h) and at 1.5 h, 3.5 h, 5 
h, 7.5 h and 10 h to trace the in vivo movement and behavior 
of capsules in the gastrointestinal tract. X-ray images of the 
rabbits in prone position were captured using L&T Vision 
100 (C-arm) X-ray machine (Larsen and Tourbo Limited, 
Mumbai, India), at 64 mAs and 63 kV voltage.
·	 In vivo pharmacokinetics study
New Zealand white rabbits weighing 3–3.5 kg were 
classified in two groups, namely standard and test with 
three animals in each group. The animals were fasted 
overnight with free access to water. The standard group 
received 5-FU aqueous solutions (10 mg/kg), while the 
test group received colon targeted capsules (ECHC-3). 
At appropriate intervals, blood samples (approximately 1 
ml) were withdrawn from the marginal ear vein. 5-FU was 
extracted from plasma by mixing rabbit plasma with ethyl 
acetate and isopropyl alcohol (85/15, v/v). The samples 
were then dried with N2 at 37 °C and the dehydrated 
samples were dissolved in 400 μl of mobile phase for 
subsequent HPLC. The concentration of releasing 5-FU 
was measured using reversed-phase HPLC (HP1100 
Liquid Chromatography, Agilent). A Hypersil C18 (5 μm, 
ID 4.6 mm × 300 mm) analytical column was used with 
a mobile phase of 0.01 mol/L phosphate buffer (pH 3.0) 
and an elution rate of 1.0 mL/min at room temperature. 
Absorbance at 269 nm was monitored and pharmacokinetic 
parameters were determined from the absorbance-time 
curves. This method provided complete separation with a 
corresponding retention time of 7.0 minutes for 5-FU. The 
area under the plasma drug concentration–time curve was 
calculated using the trapezoidal rule. The maximal plasma 
concentration of drug (C max) and the time to reach the 
maximum plasma concentration (T max) were directly 
obtained from plasma data (Ramasamy et al., 2011). 
The data from different formulations were compared for 
statistical significance by one-way analysis of variance 
(ANOVA). All results were expressed as mean ± S.D.
RESULT AND DISCUSSION
Method development for the fabrication of 
microsponges
In present research work, sodium chloride was used as 
porogen, based on the considerations that the use of hydrogen 
peroxide and sodium bicarbonate as porogen resulted in the 
evolution of gases like nascent oxygen or carbon dioxide 
that may be incompatible with active pharmaceutical 
ingredients. Sodium chloride as a porogen is inert in terms 
of the evolution of gas and its high aqueous solubility would 
facilitate its easy extraction in the outer aqueous phase 
during the microsponge formation (Orlu, Cevher, Araman, 
2006). Therefore, using sodium chloride as porogen, nine 
formulations (F1-F9) were fabricated and characterized.
Characterizations of microsponges
·	 Morphological studies and rheological characteriza-
tion
Micrographs of optimized drug loaded microsponges 
A. Gupta, G. Tiwari, R. Tiwari, R. Srivastava, A. K. Rai596
F4 confirmed the highly porous nature of microsponges. 
SEM of microsponges before in vitro release test in Figure 
1 (A and B) depicted spherical, smooth surfaced and 
uniformly porous particles. Figure 1 (C and D) magnified 
the surface view of microsponges F4 will show its highly 
cross linked polymeric surface containing numerous 
interconnected voids loaded with drug thus supporting 
the spongy nature of microsponges. Figure 1 (E and F) 
is the micrographs of microsponges F4 after the in vitro 
drug release for 8 h and it depicted irregular microsponges 
with numerous regular striations due to erosion of surface 
associated drug molecules.
·	 Powder X- ray diffraction studies (PXRD)
The X-ray diffraction patterns of 5-FU and 5- FU 
loaded microsponges plotted by using origin software are 
shown in Figure 2.The PXRD pattern of 5-FU showed 
peaks at 29◦, 33◦, 16◦, 19◦, and 21◦ which were intense and 
sharp indicating its crystalline nature also supported by 
the literature (Zhang et al., 2011). Some of these 5 -FU 
peaks are also present in diffractogram of 5-FU loaded 
microsponges, due to surface adsorbed drug. Since 
Eudragit RS 100 has ammonio methacrylate units that 
confer a positive charge on the polymer surface while 
5-FU has a negative charge on its surface. Therefore 
the drug molecule can undergo ionic adsorption on 
the surface of the polymer. However, 5-FU loaded 
microsponges presented most of the peaks of diminished 
intensity indicating that there might be partial or complete 
transitions of drug entrapped in microsponges from 
crystalline state to an amorphous state.
·	 Thermal analysis
TGA-DSC thermograms of pure 5-FU and drug 
loaded microsponges are depicted in Figure 3. The 
extrapolated onset temperature in thermograms denotes 
the temperature at which the weight loss begins. The 
extrapolated onset temperature of 5-FU is 286.9 oC. 
The DSC thermogram of the pure 5-FU also showed a 
sharp melting endotherm peak at approximately 286.9 
°C followed by decomposition, which was in agreement 
with those reported previously (Lee et al., 2003). The red 
curve is the % weight loss curve and it indicated that % 
Weight loss occurs in one step with 90% decomposition 
of the drug between 280 °C to 350 °C. Drug-loaded 
Optimized microsponges showed TGA extrapolated 
onset temperature at 280 °C and 365 °C indicating the 
presence of small drug in crystalline form which might 
be due to small amount of drug adsorbed onto the surface 
of the microsponges whereas a shifted small broad 
endothermic peak at 351 oC suggested that the drug 
was either totally or partially converted into amorphous 
form and further no characteristic peak of 5-FU was 
observed. The reduction of height and sharpness of the 
endotherm peak may be due to the presence of polymers 
in the microsponges. TGA thermograms of microsponges 
also showed a downward shift which indicated loss of 
mass (due to solvent evaporation, loss of moisture and 
degradation) upon heating. The red curve, which is the % 
FIGURE 1 - SEM of Microsponges F4 before drug release (A 
and B), surface view of F4 before drug release (C and D), F4 
after drug release (E and F).
FIGURE 2 - X-ray diffraction patterns of 5-FU & F4 (optimized 5-FU loaded microsponges).
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weight loss curve showed % weight loss in two steps. In 
the first step, 20% weight loss between 260 oC to 290 oC 
indicated decomposition of surface adsorbed drug present 
in crystalline form and in the second step, 70% weight 
loss in a temperature range of 340 oC to 410 oC suggested 
the decomposition of amorphous form of drug entrapped 
within the microsponges. Therefore, physical status of 
drug present in microsponges was in correlation with 
PXRD data.
Particle size
The particle size of the microsponges ranged between 
41.48 µm (F2) and 75.02 µm (F9) (Table II). On applying 
one-way ANOVA, it was observed that the experimental 
design had significant influence on the particle size. As the 
amount of the drug to be incorporated was kept constant, 
any change in particle size was influenced by the variation 
in the levels of ERS100 (polymer) and the volume of 
organic solvent. At the lowest level of organic solvent, the 
microsponges F2, F5 and F7 with mean diameter 61.22 
µm, 71.48 µm and 75.02 µm respectively were obtained. 
However, on increasing the volume of organic solvent, 
microsponges with smaller diameter were formulated. 
Thus F4 and F9 yielded smaller microsponges of 42.15 
and 58.31 respectively. Also at low levels of polymer 
content, microsponges F2, F4 and F6 with a mean 
diameter of 61.22 µm, 42.15 µm, and 55.32 µm, were 
obtained. However, on increasing the polymer content, 
microsponges with larger diameter were formulated, i.e. 
F1, F5 and F8 with a mean diameter of 69.40 µm, 71.48 
µm and 65.31 µm respectively, were obtained. Therefore, 
it was interpreted that a higher concentration of polymer or 
a lower level of organic solvents produced a more viscous 
dispersion, which formed larger droplets and consequently 
larger microsponges obtained.
Entrapment efficiency
The level of organic solvent and level of polymer 
also had significant influence on the entrapment efficiency. 
The entrapment efficiency was observed to increase 
with an increase in the level of organic solvent that can 
be attributed to better solubilisation of the drug in the 
organic medium. The Higher volume of the organic 
solvent resulted in the more uniform mixing of the drug 
and polymer resulting in a more uniform matrix with high 
drug entrapment efficiency. Microsponges F1, F4 and F 9 
with high level of organic solvent had a high percentage 
of EE 58.02%, 59.05%, and 60.82% respectively. Whereas 
Microsponges F2 and F7 had the lowest percentage of 
entrapment efficiency, i.e. 35.56% and 46.14% due to 
low level of organic solvent. Similarly, on increasing 
polymer content entrapment efficiency, increased, i.e. (F1) 
58.02% and (F8) 54.87% had a high entrapment efficiency, 
whereas microsponges with low level of polymer content 
had less entrapment efficiency i.e. (F2) 35.56% and (F6) 
47.40 % (Table II).
Along with above two factors a third factor, 
i.e. particle size also found to have an impact on the 
entrapment efficiency. The observations suggested that 
entrapment efficiency of the microsponges increased with 
the decrease in the particle size. Consequently F4 and 
F9 with particle size 42.15 µm and 58.31 µm had high 
EE %, i.e. 59.05% and 60.82%, whereas F2 and F7 with 
particle size 61.22 µm and 75.02 µm had low EE i.e. % 
35.56 %and 46.14% respectively. Therefore, Particle size 
also had an impact on the entrapment efficiency, but it 
was not statistically significant. Drug Content and Drug 
Loading of microsponge’s ranged from 52.2 % (F2) to 
85.2% (F9) and 15.98 % (F6) to 39.75 % (F4) respectively 
(Table II).
FIGURE 3 - TGA-DSC thermograms of pure 5-FU drug and 5-FU loaded Microsponges.
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In vitro drug release study
The percent cumulative drug release in the SCF 
was observed between 90.52% (F6) to 97.58% (F9) 
suggesting the ability of the microsponges to release the 
drug completely (Table II). All the formulations followed 
zero order release kinetics (Figure 4) except F2 and F8 that 
followed Higuchi and Peppas release kinetics. Zero order 
release of drug from microsponges, has been reported by 
researchers (Devrim, Canefe, 2006). The mechanism of 
drug release from microsponges as explained by various 
researchers is co-relatable to its porous surface. The porous 
surface of the carrier particle enables easy penetration of 
the release media and its accessibility to the entrapped 
drug molecule. In case of F2 and F4, a high initial rate of 
the drug release in 2–3 h was observed due to the surface 
adsorbed drug molecule that underwent quick release to 
attain the Equilibrium with the dissolved drug molecule, 
Additionally, as suggested by various research reports, 
control on the drug release can also be achieved by 
uniform mixing of the drug and polymer in organic media 
to form homogenous phase.F2 and F7 formulated with low 
levels of polymer and organic phase might have resulted 
in the improper encapsulation of the 5-FU in the ERS 100 
matrix. Due to this, majority of the drug molecules resided 
on the particulate surface as adsorbed molecules and had 
the probability of undergoing quick solubilisation and 
hence quick drug release. But after achieving equilibrium, 
the rate of drug release decreased. This effect was not 
predominant in F9 as it is constituted of intermediate level 
of ERS and high level of organic phase. While in F5, the 
release fitted first order model that may be due to the fact 
that the drug release from the polymeric microsponge 
occurs on transition of the polymer, and as the amount of 
polymer in microsponges increases the time required for 
phase conversion also increases. Thus, in F8, the initial 
drug release was due to the adsorbed molecules but with 
the lapse of time, ERS layer underwent transition resulting 
in the abrupt or burst release of 5-FU.
Statistical analysis
Statistical analysis was done by Design expert 
software version 8.0.7.1 (Stat-Ease, Inc., Minneapolis, 
USA) and the second order polynomial equations were 
derived. The statistical model incorporating interactive 
and polynomial terms was utilized to evaluate the 
responses. Response surface plot (Figure 5) and 3-D Bar 
Graph (Figure 6) clearly depicts the effects of independent 
variables, i.e. varying the levels of volume of organic 
solvent and polymer content over dependent variables (i.e. 
Particle size, % EE and % CDR).
TABLE II - Compilation of evaluation parameters of 5-FU loaded microsponges
Formulation code Particle size (µm) Drug content (%) Drug loading (%) EE (%) % CDR
F1 69.40 ± 1.34  79.01±0.52 21.97±0.09 58.02±0.20 95.92±0.12
F2 61.22 ± 0.65  52.20±1.06 25.48±0.14 35.56±0.32 93.69±0.07
F3 61.34 ± 0.34  84.54±0.21 23.76±0.54 50.27±0.26 92.54±0.11
F4 42.15 ± 0.28  69.29±0.43 39.75±0.17 59.05±0.31 97.07±0.13
F5 71.48 ± 0.42 72.43±1.15 15.98±0.23 50.02±0.19 94.54±0.03
F6 55.32± 0.25 57.65±0.26 31.32±0.08 47.40±0.16 90.52±0.02
F7 75.02 ± 0.34 58.39±0.72 26.98±0.11 46.14±0.37 93.48±0.06
F8 65.31± 0.92 76.58±0.16 19.71±0.21 54.87±0.31 91.78±0.15
F9 58.31 ± 0.28 85.01±0.29 27.93±0.14 60.82±.015 97.58±.0.02
F10+ 50.5838 - - 59.3045 97.2196
+ Predicted value, % EE: Percent Entrapment Efficiency, % CDR: Percent Cumulative Drug Release. *All the values are expressed 
in Mean ± SD
FIGURE 4 - In vitro drug release profile of 5-FU loaded 
microsponge formulations (F1-F9).
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Factorial equation for particle size
The Response Surface linear model generated for 
particle size was found to be significant with an F-value 
of 11.30 (p< 0.0500) and correlation coefficient of 0.9824.
Particle Size (Y1) = 62.17 - 6.31 X1+ 7.92 X2 -1.52 X12 + 
2.72 X22 + 3.94 X12X2 + 3.06 X1 X22 – 2.03 X12X22
The co-efficient of X1 is negative, indicating that 
when the volume of organic solvent increased, the particle 
size decreased, whereas the positive coefficient of X2 
indicates that particle size increased on increasing polymer 
content. The P value for variable X1 and X2 were 0.0252 
and 0.0099 respectively (p< 0.0500) indicated that both the 
independent variables show significant effect on dependent 
variable i.e. particle size.
Factorial equation for % EE
The Response Surface linear model generated for 
particle size was found to be significant with an F-value 
of 63.59 (p< 0.0500) and correlation coefficient of 0.9745.
% EE (Y2) = 51.350 + 7.695 X1 + 3.483 X2 – 3.872 X1X2
The positive co-efficient of X1 and X2 indicates that 
% EE increases on increasing volumes of organic content 
as well as polymer content. Whereas the combination of 
independent variables X1X2 had a negative influence on 
% EE. The P value for variable X1, X2 and X1X2 were 
0.0001, 0.0031 and 0.0047 respectively (p< 0.0500) show 
that both the independent variables as well as combination 
of independent variable had a significant effect on 
dependent variable i.e. % EE.
Factorial equation for % CDR
The Response Surface linear model generated for % 
CDR was found to be significant with an F-value of 11.55 
(p< 0.0500) and correlation coefficient of 0.9506.
% CDR (Y3) = 92.022 + 1.476X1 + 3.766 X1
2
+ 0.160 X2 
– 0.613 X2
2 - 0.500X1X2
According to above factorial equation Independent 
variables X1, X12 and X2 had a positive influence on % 
CDR. Whereas the combination of independent variables 
X1X2 and X22 had a negative influence on % CDR. The X1 
and X12 with p value 0.0250 and 0.0087 respectively, were 
significant model terms (p< 0.0500) whereas X2, X1X2 and 
X22 were insignificant model terms.
FIGURE 5 - Response surface plot depicting the influence of independent variables over dependent variables.
FIGURE 6 - 3D bar graph depicting the influence of independent variables over dependent variables.
A. Gupta, G. Tiwari, R. Tiwari, R. Srivastava, A. K. Rai600
Validation of the experimental design
The results of experimentally observed responses 
and those predicted by mathematical models along 
with the percentage prediction errors were compared. 
The prediction error in the response parameters ranged 
between 0.51 and 1.15% with the value of absolute error 
of 1.28 ± 0.70%. Lower values of error indicate the high 
prognostic ability of factorial equation and counter plot 
methodology. “Adeq Precision” measures the signal to 
noise ratio. A ratio greater than 4 is desirable. The ratio of 
8.505 indicates an adequate signal. Thus, this model can 
be used to navigate the design space.
Selection of optimized formulation
Microsponge formulation F4 with highest 
desirability factor of 0.944 having smallest particle size of 
42.15 ± 0.28 µm, maximum % entrapment efficiency and 
% CDR of 59.05±0.31 and 97.07±0.13 respectively was 
selected as optimized formulation. Ramps reports clearly 
depict criteria’s for selection of optimized formulation 
(Figure 7). F4 was further used for preparation of colon 
target capsules.
Modification of pectin to calcium pectinate
Use of Calcium pectinate beads as a plug in colon 
target capsules was a novel step and the rationale behind 
this was that calcium pectinate (the insoluble salt of pectin) 
is not degraded by gastric or intestinal enzymes, but will be 
degraded by colonic pectinolytic enzymes and hence now 
our formulation would be microbial triggered. Calcium 
pectinate is a natural polymer which can be used as a 
major component or filler in pharmaceutical composition 
that could be degraded by only colonic enzymes (Jain, 
Gupta, Jain, 2007). Pectin is one of the most widely 
investigated polysaccharides in the colon-specific drug 
delivery. It can be broken down by pectinase enzymes 
produced by anaerobic bacteria in the colon and control 
the drug release by this principle. It can also act via the 
pH- and time controlled mechanisms. However, due to 
high water solubility and swelling, pectin is not capable of 
shielding the drug effectively during the passage through 
the stomach and small intestine. Therefore Pectin with low 
degrees of methoxylation (i.e., low methoxypectins or LM 
pectin) was cross-linked with calcium ions (Ca2+, divalent 
cations) to produce Ca- pectinate networks that were less 
water soluble (Bourgeois et al., 2006). Indeed, Ca2+ ions 
form “bridges” between the free carboxylated groups of 
galacturonic acid moieties. The network that is formed has 
been described by Grant et al. under the name of «egg-box 
model». Pectin with DM < 50% (i.e., LM pectin) was used 
because it contains more free carboxylic group than high 
methoxy pectin (HM pectin). Therefore, cross-linking 
between divalent cations (e.g., Ca2+) and free carboxylic 
groups of the pectin are more evident in LM pectin than 
HM pectin (Badve et al., 2007). The spherical beads were 
easily prepared without any sophisticated instrument 
due to ionic interaction between the negatively charged 
carboxylic groups of pectin molecules and the positively 
charged divalent calcium ions which led to intermolecular 
cross-linking and instantaneously produced gelled sphere 
(Sriamornsak, Thirawong, Puttipipatkhachorn, 2005).
Characterization of calcium pectinate beads
Size, surface morphology and rheological 
characterization
Particle size of calcium pectinate beads was of approx 
105.22 ± 3.36 µm. SEM of pectin demonstrated smooth 
doughnut shaped particles more or less, of uniform size 
(Figure 8G) and calcium pectinate beads were spherical 
with smooth surfaced (Figure 8H). Analysis of the 
rheological characteristics of calcium pectinate confirmed 
good rheological properties with bulk and tapped density of 
0.504 g/cm3 and 0.558 g/cm3, Carr’s compressibility index 
of 9.67 % and Angle of repose of 20.56 º indicated good flow 
properties of calcium pectinate beads.
FIGURE 7 - Numerical optimization ramps report.
FIGURE 8 - SEM of Pectin (G) and Calcium Pectinate beads (H).
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·	 Swelling characteristics
Pectin and calcium pectinate were compared for 
their swelling characteristics. No significant swelling was 
observed for calcium pectinate (swelling ratio of 0.11± 
0.04) as compared to pectin, which swelled considerably 
with a swelling ratio of 0.98 ± 0.02. The reduction in 
swelling of the calcium pectinate in SIF (pH 7.4) presents 
its feasibility to be used as a carrier for the colon-targeted 
drug delivery.
Preparation of enteric coated HPMC capsules
EUDRAGIT® L and S grades are suitable for enteric 
coatings and are specifically used for controlled release in 
the colon (Ramasamy et al., 2011). Coatings on the gelatin 
capsules often suffer from insufficient adhesion between 
the shell and the coating. Thus, previous workers in the 
area of enteric coating have found it necessary to pre-coat 
gelatin capsules with, for instance, a cellulose derivative, 
either to promote adhesion of polymers to the capsule shell 
or to improve gastric-resistance (Cole et al., 2002). When 
the capsule itself is made of a cellulose derivative it would 
be expected, based on the experience with enteric coating 
of tablets with a pre-coating of HPMC, that a pre-coating 
step could be eliminated. Gelatin capsules have a very 
glossy surface due to the fact that the amount of regular 
reflection from the surface is high and the amount of 
diffuse reflection is low. In contrast, HPMC capsules have 
a visually matt surface with a greater amount of diffuse 
reflection, suggesting a more irregular surface. SEM’s 
of the surface of HPMC and gelatin capsules are shown 
in Figure 9 (I) and Figure 9 (J) where this difference is 
clearly visible. During the coating process the temperature 
of the capsule bed reaches 25–27 °C. At this temperature 
HPMC is soluble and will start to dissolve in the eudragit 
film providing a strongly adhesive surface. Gelatin, on the 
other hand, is only slightly soluble at this temperature and 
its surface characteristics will remain virtually unchanged. 
Figure 9 (K) shows SEM of the cross-section of a cleaved 
surface through an HPMC capsule coated with EdS100 
solution. The contours of the coating material are seen 
to follow the irregular surface of the HPMC capsule. It 
is suggested that the high strength of the bond between 
HPMC and the film is a combination of the irregular 
surface and the tackiness of the partially dissolved surface. 
No pores or cracks can be observed, due to the well 
controlled coating process. In addition, the critical area of 
overlap between the cap and the body of the capsule is also 
covered with EdS100 polymers to ensure gastric integrity.
Evaluation of colon target enteric coated HPMC 
capsules
Integrity test of enteric coated HPMC capsules
Results of integrity test are shown in Table III. 
ECHC-3, ECHC14 and ECHC15 which did not dissolve 
in pH 5.5 buffers were selected for further in vitro drug 
release study in simulated colonic fluid.
In vitro drug release study
In vitro drug release study was conducted in pH 
change method as per USP protocol (2 h in SGF, 2-5 h in 
SIF and 5-24 h in the SCF) and the results are shown in 
Table IV. The immediate release marketed formulation 
showed almost total release in 4 h and the pure drug in 
3 h. Nearly complete drug release of microsponges in 
TABLE III - Integrity test of enteric coated HPMC capsules
Parameters
Formulation Code
ECHC1 ECHC2 ECHC3 ECHC4 ECHC5 ECHC6 ECHC7 ECHC8 ECHC9 ECHC10 ECHC11 ECHC12 ECHC13 ECHC14 ECHC15









5 10 15 5 10 15 5 10 15 5 10 15 5 10 15
Disintegration test 
in 0.1 N HCL
F P P  F P P F P P F P P P  P P
Solubility in pH 5.5 - S NS - S S - S S - S S S NS NS
*F = Fail, P = Pass, S = Soluble, NS = Not Soluble
FIGURE 9 - SEM of a cross section of HPMC capsule surface 
(I), Gelatine capsule surface (J), and HPMC capsule surface 
coated with Eudragit S 100 (K).
A. Gupta, G. Tiwari, R. Tiwari, R. Srivastava, A. K. Rai602
HPMC capsules (97.07%) in 8 h indicated the need for 
enteric coating of capsules for colon delivery (Figure 
10). Enteric coated HPMC capsules ECHC-3, ECHC-
14 and ECHC-15 showed no drug release in simulated 
gastric fluid (pH 1.2) up to 2 h indicating the intactness of 
the applied coating. On exposure to simulated intestinal 
media, capsules coated with blend of EdS-100: EdL-100 
showed the earlier drug release as compared to capsules 
coated with only EdS-100. As the pH of solubilisation of 
EdL-100 is 6 and that of EdS-100 is 7.0, EdL-100 gets 
dissolved first and form pores. Calcium pectinate beads 
also become hydrated and forms a viscous gel layer that 
slows down further seeping -in of dissolution fluids and 
therefore release of 5-FU takes place by diffusion along 
with the erosion of eudragit layers (Sharma, Philip, Pathak, 
2008). The formulations ECHC-14 and ECHC-15 released 
15.01% and 14.56 % of 5-FU respectively, at the end of 5h 
dissolution study in intestinal media. This indicated that in 
spite of the high water solubility of 5-FU, there was tight 
control of drug release in the physiological environment 
of the stomach and small intestine. However the integrity 
of ECHC -3, was maintained after 5 h studies with no 
drug release upto 5 h this indicated that drug released was 
highly retarded on coating with EdS-100 (ECHC -3) in 
comparison to blend of EdS-100: EdL-100 coating. Visual 
observation revealed small flakes of coatings occurred 
about 3.5 h from the beginning of the release experiment. 
The release of drug from the enteric-coated capsules can 
be explained by the pore formations and bursting/ flake 
formation of the coat due to the presence of high alkaline 
pH of dissolution media.
The ECHC-3 containing 15 % calcium pectinate 
plug in ES 100 coated HPMC capsules appears to be 
promising as it did not release the cytotoxic 5-FU in the 
physiological environment of the stomach and small 
intestine . The relative advantage of ECHC-3 over the other 
formulations ECHC-14 and ECHC-15 also depend on its 
ability to release the drug in the physiological environment 
of the colon. Hence, after completing the dissolution study 
in 1.2 pH and 6.8 pH, the dissolution study was carried 
out in simulated colonic fluids (with pectinase enzyme and 
without pectinase enzyme i.e. control study) for another 
19 h. The percentage of 5-FU released from ECHC-3 at 
the end of 24 h with pectinase enzyme was found to be 
97.83 ± 0.12%, whereas in the control study (without 
pectinase enzyme in the dissolution medium) only 40.08 
± 0.02% of 5-FU was released. This difference was found 
to be statistically significant (p<0.001). This study shows 
that the release of 5-FU in a physiological environment of 
the colon is due to the microbial degradation of calcium 
pectinate plug in the presence of pectinase enzyme. The 
dissolution study was conducted without pectinase enzyme 
TABLE IV - In vitro drug release profile of ECHC
Time
Cumulative % Drug Release
ECHC 3 ECHC 14 ECHC 15
0-2 h at Gastric pH (1.2) No release No release No release
2-5 h in intestinal pH (6.8) No release 12.01±0.02 10.56±0.07
Simulated Colonic pH 7.4 Pectinase Control Study Pectinase Control Study Pectinase Control Study
6 21.03±0.01 8.17±0.02 38.02±0.04 18.03±0.02 35.12±0.05 14.06±0.01
8 39.04±0.12 15.02±0.14 50.04±0.06 26.04±0.11 49.07±0.13 22.15±0.08
10 58.22±0.03 22.08±0.13 63.21±0.08 31.21±0.07 66.15±0.04 28.07±0.13
14 77.01±0.06 29.01±0.05 76.14±0.01 35.08±0.06 79.22±0.11 34.12±0.06
18 91.02±0.04 33.09±0.06 88.11±0.03 39.01±0.11 90.23±0.02 40.01±0.02
24 97.83±0.12 40.08±0.01 96.05±0.12 44.84±0.03 97.01±0.08 46.43±0.09
*All the values are expressed in Mean ±SD
FIGURE 10 - Comparison of in vitro release profile of immediate 
release marketed tablet of 5-FU, pure 5-FU drug, 5-FU loaded 
microsponges and enteric coated HPMC capsules plugged with 
5-FU loaded microsponges and calcium pectinate beads.
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(control study) to ensure that the drug was not released due 
to the mechanical erosion, which is likely to occur because 
of bowel movements in humans. Similarly formulations 
ECHC-14 and ECHC-15 released 96.05 ± 0.05% and 
97.01± 0.08% of 5-FU respectively in the presence of 
pectinase enzyme, whereas in control study, they released 
only 44.84±0.03% and 46.34±0.09% respectively. A 
significant difference was observed (p<0.001) in the 
amount of 5-FU released from formulations ECHC-14 
and ECHC-15 at the end of 24 h with a pectinase enzyme 
as compared to in vitro release without pectinase enzyme.
All the three formulations ECHC -3, ECHC-14 and 
ECHC-15 released almost complete drug by the end of 
24 h in vitro release study in the presence of pectinase 
enzyme. The release profiles of all the three formulations 
were similar at the end of 24 h with no significant 
difference (p ≤ 0.05). HPMC capsule provided a system 
of low permeability and a good barrier to drug diffusion at 
the pH, where protection is required (Moawia, Tabakha, 
2010). Variation in coating ratios had little influence on 
the dissolution profiles of microsponges confirming the 
robustness of the formulation and the better compatibility 
between HPMC and the polymethacrylate films. Thus, 
enteric coated HPMC capsules plugged with a matrix of 
5-FU loaded microsponges and calcium pectinate proved 
to be potential candidate for targeted colonic delivery to 
treat colorectal cancer.
ANIMAL STUDIES
In vivo roentgenography study
In vivo X-ray imaging allows the visualization 
of in vivo functioning of a colon specific drug delivery 
system, thereby ascertaining the location of drug release. 
The results of X-ray imaging studies are shown in Figure 
11. Figure 11 (a) shows position of capsule just after 
the administration followed by its passage to stomach 
after 1.5 h in Figure 11 (b) thereby indicating that the 
capsule remains intact in the stomach, establishing in vivo 
efficiency of the coating of Eudragit L100 and Eudragit S 
100 in preventing drug release in the gastric milieu. Figure 
11 (c) depicts no significant difference in the integrity of 
capsules in comparison to Figure 11 (b), thereby indicating 
intactness of capsule in the small intestine at 3.5 h. The 
capsule could be traced in the small intestine at 3.5 h 
(Figure11c), intestinal colon junction at 5 h (Figure 11 d) 
and finally in colon at 7.5 h (Figure 11 e). At 10 h (Figure 
11 f) the intact capsule could not be traced demonstrating 
its erosion in the colon. These images clearly demonstrate 
the efficiency of selected formulation (ECHC-3) for its 
capacity to traverse the intestine intact and deliver the 
drug for site specific targeting of 5-FU microsponges to 
the colon.
In vivo pharmacokinetics study
Figure 12 shows the plasma concentration vs. time 
profiles of 5-FU after administration of ECHC and the 
5-FU aqueous solution to New Zealand white rabbits at a 
dose of 10 mg/kg respectively. Colon specific absorption 
of releasing 5-FU affected its pharmacokinetic parameters. 
After oral administration of the 5-FU solution, the drug was 
detected rapidly in plasma. The maximum concentration 
of 5-FU was 20 µg/mL after about 1 h. Thereafter, the 
plasma concentration decreased quickly and the drug 
was not detectable as soon as 8 h. The elimination half 
life was 0.12 ± 0.03 h. While in case of colon targeted 
enteric coated capsules (ECHC), 5-FU appeared in plasma 
after 6 h (lag time) of administration with a Cmax of 
14 µg/mL at 25 h. A lag time of 6 h for the developed colon 
targeted enteric coated capsules indicated the ability of the 
colon-targeted formulation to prevent the release of 5-FU 
in the stomach and small intestine. The Cmax, Tmax, t 1/2 
and AUC 0-∞ were significantly different from those of the 
aqueous solution. The Cmax of colon-targeted formulation 
was significantly (p < 0.001) less than the Cmax of 5FU 
solution, suggested reduced systemic absorption of the 
drug from ECHC-3. This means that a larger fraction 
of the drug was available on the colonic surface for 
local action. AUC0–∝ for aqueous solution and colon-
targeted formulation was found to be 62.5543 µg h/mL 
and 49.3412 µg h/mL, respectively. Consequently the Fr 
(relative bioavailability) of the colon-targeted tablet was 
determined as 70.18%. Thus, in vivo pharmacokinetic 
studies of enteric coated HPMC capsules plugged with 
calcium pectinate beads and 5-FU loaded microsponges 
exhibited increased lag time, delayed t max, decreased 
Cmax and reduced bioavailability. It can thus be concluded 
FIGURE 11 - X-ray images of New Zealand rabbit administered 
with colon targeted formulation (a) immediately after 
administration, (b) 1.5 h (stomach), (c) 3.5 h (small intestine), 
(d) 5 h (intestinal colon junction), (e) 7.5 h (colon) and (f) 10 h 
(rectum).
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FIGURE 12 - In vivo pharmacokinetic profile of 5-FU in New 
Zealand white rabbits following administration of 5-FU aqueous 
solution and developed colon targeted capsules.
that the developed colon targeted formulation has the 
ability to avoid the drug release in the upper GIT, but can 
release the active agent specifically in the colon exert local 
action with reduced systemic exposure.
CONCLUSION
A novel colon targeted drug delivery system that 
combined two approaches, i.e. pH-sensitive delivery as 
well as degradation by bacterial enzymes in the colon 
environment was successfully developed. This study 
clearly indicated that enteric coated HPMC capsules 
plugged with 5-FU loaded microsponges along with 
15% calcium pectinate beads provided a tight control 
over the drug release in the physiological environment 
of the stomach and small intestine in spite its high water 
solubility. Matt surface of HPMC capsule provided a good 
substrate for adhesion of enteric coating polymers and 
calcium pectinate beads also proved to be a suitable carrier 
for colon targeted system. Thus, the developed colon 
targeted drug delivery system proved to be more patient 
compliant by providing a better mode of treatment over 
present intermittent chemotherapy by injection or infusion.
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